Douglas Tsao

Sage Therapeutics Inc (NASDAQ: SAGE) shares fell more than 60% Thursday following a negative readout for its lead asset in major depressive disorder. The Analysts Morgan Stanley analyst Matthew Harrison maintained an Overweight rating for Sage but lowered the price target from $217 to $125. (See...

Impax Laboratories Inc (NASDAQ: IPXL) announced an agreement in October to merge with privately held Amneal Pharma, with 75 percent of the combined company held by Amneal shareholders and 25 percent by Impax Labs shareholders. The FTC recently laid down conditions — including the...

Mallinckrodt PLC (NYSE: MNK) agreed to buy Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) in a deal announced in December. The Analyst Weighing in the planned acquisition, Barclays analyst Douglas Tsao downgraded shares of Mallinckrodt from Equal Weight to Underweight and lowered the price...

Allergan plc Ordinary Shares (NYSE: AGN) is down 26 percent over the last six months, but one analyst said there's only upside to its sickly state. The biotech’s trajectory inspired an upgrade from a three-year Hold. The Rating Barclays analyst Douglas Tsao upgraded Allergan to a Buy...

Specialty pharma company Mallinckrodt PLC (NYSE: MNK) reported disappointing  results before the open Tuesday,with the weakness stemming from soft sales of its key drug Acthar, which fetched roughly 52 percent of the total sales. Acthar gel is an injectable formulation used to treat...

Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) hit a new 52-week low of $37.25 on Tuesday after the company reported its third-quarter results and provided a concerning outlook for the full year given some concerns over its specialty drugs. The stock rebounded slightly on Wednesday...

Barclays’ Douglas Tsao believes the Q3 results reported by Valeant Pharmaceuticals Intl Inc (NYSE: VRX) proved there are no easy fixes for the challenges being faced by the company, despite the increased transparency. Tsao maintained an Equal Weight rating on the company, with a price...

Barclays said in a research note that it sees 44–48 percent upside in Perrigo Company plc Ordinary Shares (NYSE: PRGO) to $131–$138, given its view that a more focused company could optimize performance of its consumer healthcare and branded healthcare business. The firm sees $1.60...

Mylan NV (NASDAQ: MYL) has received overwhelming criticism, even inciting mention from Hillary Clinton, for increasing the price of its life-saving EpiPen product 400 percent while raising the Mylan CEO’s salary by 600 percent. Company shares have begun to rebound Thursday, however, due to...

Things seem to keep getting worse and worse for Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and its shareholders, including last week’s deep guidance cut. Barclays analyst Douglas Tsao believes Valeant’s new management team is taking steps in the right direction, but the journey will...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) reported its 1Q16 EPS significantly short of expectations. Barclays’ Douglas D. Tsao maintained an Equal Weight rating for the company, with a price target of $34. Disruptions To Continue Analyst Douglas Tsao commented that disruption in...

Since August, Mallinckrodt PLC (NYSE: MNK) declined 44 percent. Barclays' Douglas Tsao slashed its price target by more than 20 percent from $130 to $100. Tsao said that it's "hard to imagine sentiment" for Mallinckrodt worsening, but noted that there are upcoming events that might help stem the...